Optimizing DMARD Therapy in Rheumatoid Arthritis A phase IV trial from Spain demonstrates that optimization of therapy by lessening biological DMARDs in rheumatoid arthritis (RA) may be feasible, with a low risk of flare. https://t.co/37O3mAulGy https://t.co/y7OkkzRZUg